Log in
Enquire now
‌

CFD Research Corporation STTR Phase II Award, August 2020

A STTR Phase II contract was awarded to CFD Research Corporation in August, 2020 for $999,974.0 USD from the U.S. Department of Defense and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1920159
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
CFD Research Corporation
CFD Research Corporation
0
Government Agency
U.S. Department of Defense
U.S. Department of Defense
0
Government Branch
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
0
Award Type
STTR0
Contract Number (US Government)
W911QY-20-C01060
Award Phase
Phase II0
Award Amount (USD)
999,9740
Date Awarded
August 14, 2020
0
End Date
August 31, 2022
0
Abstract

In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens, whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial and alphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and rapid diagnostics. We propose to undertake a systematic in vivo study to identify and validate the circulatory RNAs and exosomal-based biomarkers of Venezuelan equine encephalitis virus, Rickettsia prowazekii, and Brucella abortus infections. Multiple clinical matrices (urine, blood) and infection routes will be studied to analyze the RNA biomarker dynamics in a specified diagnostic window (0-14 days, post infection). Exosome contents (e.g., miRNA) and other host-based biomarkers will also be analyzed and compared for specificity and sensitivity. Finally, we will integrate the animal outcome in computational models to predict pathogen kinetics, translation of findings from animals to humans, and to make predictions of prognostic factors for treatment efficacy and the risk of relapse and progression. Ultimately, we envision to develop a low cost, in vitro diagnostic device for rapid and sensitive detection of pre-symptomatic, symptomatic or convalescent biomarkers of these infectious diseases.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like CFD Research Corporation STTR Phase II Award, August 2020

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.